RA Capital Management is a thesis-driven, evidence-based multi-stage investment firm focused primarily on healthcare and life sciences, investing across private and public markets from company formation through commercialization. The firm underwrites scientific and technical validation rather than company age, using deep internal research capabilities such as TechAtlas and incubation through Raven to build high-conviction positions globally.
RA Capital invests when a company demonstrates strong scientific or technical validation and a clear, data‑driven path to further validation, emphasizing the amount of time and capital required to reach that point. The first meeting, typically led by a TechAtlas associate, gathers high‑level context; a second, often confidential meeting refines the view of what data are needed to reach a decision, and the process can be compressed to one‑to‑two weeks for time‑sensitive deals. Deal‑breakers include late‑stage, high‑risk scenarios such as a public company pursuing a Phase 3 trial based on post‑hoc analysis of a failed Phase 2 study, or any situation where the validation pathway is ambiguous. In early diligence, technology, data, and business model dominate; as the process advances, the team places increasing weight on the founders and management team, especially when RA intends to take board seats or provide operational support. The firm prefers co‑investors who conduct deep diligence and can write large checks, aligning with its long‑term value‑creation focus and reducing the likelihood of short‑term exit pressure.
See the rest of how RA Capital Management decides.
Evaluation framework, investment themes, pitch guidance and the partner map. One email, no password — we send a link and you land right back here.